Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

248
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
248
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

849
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
849
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance01:23

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

278
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
278
Factors Affecting Protein-Drug Binding: Patient-Related Factors01:29

Factors Affecting Protein-Drug Binding: Patient-Related Factors

94
Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
94
Parenteral Anesthetics: Overview01:24

Parenteral Anesthetics: Overview

185
Intravenous anesthetics are drugs administered parenterally to induce anesthesia or sedation. Propofol is a widely used agent formulated as a 1% emulsion in soybean oil, glycerol, and egg phosphatide. It induces rapid anesthesia primarily due to its rapid distribution from the bloodstream to target tissues and is metabolized in the liver. However, it can cause significant pain on injection and hypertriglyceridemia. Fospropofol, a water-based prodrug of propofol, lacks these adverse effects.
185
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

140
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
140

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Extracorporeal life support in adult critically ill patients: mechanisms of benefit in respiratory and cardiac failure.

American journal of respiratory and critical care medicine·2026
Same author

CHK1 inhibition rescues abnormal glycogen buildup in a Caenorhabditis elegans model for glycogen storage disease III.

Communications biology·2026
Same author

Comprehensive Overview of Hypernatremia: Pathophysiology, Diagnosis, and Management.

British journal of hospital medicine (London, England : 2005)·2025
Same author

Close outpatient follow-up associated with reduced readmission rates in patients with inflammatory bowel disease.

Proceedings (Baylor University. Medical Center)·2024
Same author

Implementation of a multidisciplinary process to improve diagnostic stewardship of hospital-onset Clostridioides difficile infections.

American journal of infection control·2023
Same author

A Comparison of Long-Term Outcomes in Patients Managed With Venovenous Extracorporeal Membrane Oxygenation in the First and Second Waves of the COVID-19 Pandemic in the United Kingdom.

Critical care medicine·2023

Related Experiment Video

Updated: Aug 23, 2025

Identification of the Source of Secreted Proteins in the Kidney by Brefeldin A Injection
10:15

Identification of the Source of Secreted Proteins in the Kidney by Brefeldin A Injection

Published on: November 10, 2021

1.9K

Cefazolin-induced hypoprothrombinemia.

Mallory Smith1, James Doyle1, Cameron Crane1

  • 1Department of Internal Medicine, Baylor Scott & White Medical Center - Temple, Temple, Texas.

Proceedings (Baylor University. Medical Center)
|October 28, 2022
PubMed
Summary

Long-term antibiotic use, like cefazolin, can cause rare side effects. This case highlights spontaneous retroperitoneal hematoma in a patient with normal kidney function, a rare cefazolin-induced coagulopathy.

Keywords:
Cefazolincephalosporincoagulopathy

More Related Videos

Ferric Chloride-induced Thrombosis Mouse Model on Carotid Artery and Mesentery Vessel
07:26

Ferric Chloride-induced Thrombosis Mouse Model on Carotid Artery and Mesentery Vessel

Published on: June 29, 2015

17.7K
Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
06:51

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

Published on: December 10, 2016

12.7K

Related Experiment Videos

Last Updated: Aug 23, 2025

Identification of the Source of Secreted Proteins in the Kidney by Brefeldin A Injection
10:15

Identification of the Source of Secreted Proteins in the Kidney by Brefeldin A Injection

Published on: November 10, 2021

1.9K
Ferric Chloride-induced Thrombosis Mouse Model on Carotid Artery and Mesentery Vessel
07:26

Ferric Chloride-induced Thrombosis Mouse Model on Carotid Artery and Mesentery Vessel

Published on: June 29, 2015

17.7K
Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
06:51

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

Published on: December 10, 2016

12.7K

Area of Science:

  • Pharmacology
  • Internal Medicine
  • Nephrology

Background:

  • Long-term antibiotic therapy, particularly cephalosporins, is linked to diverse side effects.
  • Common cephalosporin adverse events include dermatologic reactions and gastrointestinal disturbances.
  • Antibiotic-induced coagulopathy, often due to hypoprothrombinemia, is a recognized but infrequent complication.

Observation:

  • A rare case of spontaneous retroperitoneal hematoma is presented.
  • This event occurred during cefazolin administration for vertebral osteomyelitis.
  • The patient exhibited normal renal function at the time of the adverse event.

Findings:

  • Cefazolin, a cephalosporin antibiotic, was implicated in causing coagulopathy.
  • This contrasts with most reported cases of cefazolin-induced coagulopathy, which typically involve patients with renal impairment.
  • The presented case expands the understanding of cefazolin's potential to induce bleeding complications even in patients with preserved kidney function.

Implications:

  • Clinicians should be vigilant for rare bleeding complications associated with cefazolin, even in patients with normal renal function.
  • This case underscores the importance of monitoring coagulation parameters in patients on long-term cefazolin therapy.
  • Further research may be warranted to elucidate the precise mechanisms of cefazolin-induced coagulopathy in non-renal failure settings.